Dr. Swayampakula Ramakanth
Recent Articles
Biopharma Shares Multiple 2025 Catalysts 01/17/2025
Innate Pharma SA's (IPHA:NASDAQ; IPH:Paris) long-term corporate strategy led to it recieving a Buy rating from H.C. Wainwright & Co.
Boston Biotech Reports Promising Interim Data 08/07/2024
Interim efficacy data reported for Elevation Oncology Inc.'s (ELEV:NASDAQ) EO-3021 as a monotherapy is competitive and potentially could be superior as a combination therapy, according to an H.C. Wainwright & Co. research note.
Due to permission requirements, not all quotes are shown.
